drugset
drugset / Trial / NCT00958841

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

NCT00958841 ↗

Phase 2 Terminated 118 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.

Timeline

Start
2009-09
Primary completion
2015-06
Completion
2015-06

Outcome

Outcome not reported

Stopped (Enrollment): “Slow recruitment rate into this study with rare tumors of neuroendocrine origin (enrollment issues)”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pasireotide Other / unclassified 60 mg —

Indications

Nelson syndrome ectopic ACTH secretion syndrome pancreatic neoplasm